Sponsors: []Modifications:      26-59-101.This chapter is known as "Cannabinoid Medicine Research Act."     26-59-102.As used in this chapter:(1)  "Approved study" means a medical research study:(a)  the purpose of which is to investigate the medical benefits of cannabinoid medicine;and(b)  that is approved by an IRB.(2)  "Cannabinoid medicine" means the same as that term is defined in Section58-37-3.6.(3)  "Cannabis" means the same as that term is defined in Section 58-37-3.6.(4)  "Institutional review board" or "IRB" means an institutional review board that isregistered for human subject research by the United States Department of Health and HumanServices.     26-59-103.(1)  A person conducting an approved study may, for the purposes of the study:(a)  process cannabinoid medicine or expanded cannabinoid medicine;(b)  possess cannabinoid medicine or expanded cannabinoid medicine; and(c)  administer a product containing cannabis, cannabinoid medicine, or expandedcannabinoid medicine to an individual in accordance with the approved study.(2)  A person conducting an approved study may:(a)  import cannabis, cannabinoid medicine, or expanded cannabinoid medicine fromanother state if:(i)  the importation complies with federal law; and(ii)  the person uses the cannabis, cannabinoid medicine, or expanded cannabinoidmedicine in accordance with the approved study; or(b)  obtain cannabis, cannabinoid medicine, or expanded cannabinoid medicine fromthe National Institute on Drug Abuse.(3)  A person conducting an approved study may distribute, outside the state, cannabis,cannabinoid medicine, or expanded cannabinoid medicine if:(a)  the distribution complies with federal law; and(b)  the distribution is for the purposes of, and in accordance with, the approved study.     58-37-3.6.(1)  As used in this section:(a)  "Cannabinoid medicine" means a product intended for human ingestion that:(i)  contains an extract or concentrate that is obtained from cannabis;(ii)  is prepared in a medicinal dosage form; and(iii)  contains at least 10 units of cannabidiol for every one unit of tetrahydrocannabinol.(b)  "Cannabis" means any part of the plant cannabis sativa, whether growing or not.(c)  "Drug paraphernalia" means the same as that term is defined in Section 58-37a-3.(d)  "Expanded cannabinoid medicine" means a product intended for human ingestionthat:(i)  contains an extract or concentrate that is obtained from cannabis;(ii)  is prepared in a medicinal dosage form; and(iii)  contains less than 10 units of cannabidiol for every one unit oftetrahydrocannabinol.(e)  "Medicinal dosage form" means:(i)  a tablet;(ii)  a capsule;(iii)  a concentrated oil;(iv)  a liquid suspension;(v)  a transdermal preparation; or(vi)  a sublingual preparation.(f)  "Tetrahydrocannabinol" means a substance derived from cannabis that meets thedescription in Subsection 58-37-4(2)(a)(iii)(AA).(2)  Notwithstanding any other provision of this chapter, an individual who possesses ordistributes cannabinoid medicine or expanded cannabinoid medicine is not subject to thepenalties described in this title for the possession or distribution of marijuana ortetrahydrocannabinol to the extent that the individual's possession or distribution ofcannabinoid medicine or expanded cannabinoid medicine complies with Title 26, Chapter 59,Cannabinoid Medicine Research Act.If approved by two-thirds of all the members elected to each house, this bill takes effectupon approval by the governor, or the day following the constitutional time limit of UtahConstitution, Article VII, Section 8, without the governor's signature, or in the case of a veto,the date of veto override.Full text:



1     CANNABINOID MEDICINE RESEARCH2     2017 GENERAL SESSION3     STATE OF UTAH4     Chief Sponsor:  Brad M. Daw5     Senate Sponsor:   Evan J. Vickers6      7     LONG TITLE8     General Description:9          This bill enacts provisions related to research of cannabis and cannabinoid medicine.10     Highlighted Provisions:11          This bill:12                allows a person to possess cannabis, cannabinoid medicine, and expanded13     cannabinoid medicine and to distribute the cannabis, cannabinoid medicine, or14     expanded cannabinoid medicine to a patient pursuant to an institutional review15     board-approved study; and16                allows a person conducting an institutional review board-approved study to import17     and distribute cannabis, cannabinoid medicine, and expanded cannabinoid medicine18     under certain circumstances.19     Money Appropriated in this Bill:20          None21     Other Special Clauses:22          This bill provides a special effective date.23     Utah Code Sections Affected:24     ENACTS:25          26-59-101, Utah Code Annotated 195326          26-59-102, Utah Code Annotated 195327          26-59-103, Utah Code Annotated 195328          58-37-3.6, Utah Code Annotated 195329      30     Be it enacted by the Legislature of the state of Utah:31          Section 1.  Section 26-59-101 is enacted to read:32     CHAPTER 59. CANNABINOID MEDICINE RESEARCH ACT33          26-59-101. Title.34          This chapter is known as "Cannabinoid Medicine Research Act."35          Section 2.  Section 26-59-102 is enacted to read:36          26-59-102. Definitions.37          As used in this chapter:38          (1)  "Approved study" means a medical research study:39          (a)  the purpose of which is to investigate the medical benefits of cannabinoid medicine;40     and41          (b)  that is approved by an IRB.42          (2)  "Cannabinoid medicine" means the same as that term is defined in Section43     58-37-3.6.44          (3)  "Cannabis" means the same as that term is defined in Section 58-37-3.6.45          (4)  "Institutional review board" or "IRB" means an institutional review board that is46     registered for human subject research by the United States Department of Health and Human47     Services.48          Section 3.  Section 26-59-103 is enacted to read:49          26-59-103. Institutional review board -- Approved study, cannabis, cannabinoid50     medicine, or expanded cannabinoid medicine.51          (1)  A person conducting an approved study may, for the purposes of the study:52          (a)  process cannabinoid medicine or expanded cannabinoid medicine;53          (b)  possess cannabinoid medicine or expanded cannabinoid medicine; and54          (c)  administer a product containing cannabis, cannabinoid medicine, or expanded55     cannabinoid medicine to an individual in accordance with the approved study.56          (2)  A person conducting an approved study may:57          (a)  import cannabis, cannabinoid medicine, or expanded cannabinoid medicine from58     another state if:59          (i)  the importation complies with federal law; and60          (ii)  the person uses the cannabis, cannabinoid medicine, or expanded cannabinoid61     medicine in accordance with the approved study; or62          (b)  obtain cannabis, cannabinoid medicine, or expanded cannabinoid medicine from63     the National Institute on Drug Abuse.64          (3)  A person conducting an approved study may distribute, outside the state, cannabis,65     cannabinoid medicine, or expanded cannabinoid medicine if:66          (a)  the distribution complies with federal law; and67          (b)  the distribution is for the purposes of, and in accordance with, the approved study.68          Section 4.  Section 58-37-3.6 is enacted to read:69          58-37-3.6. Exemption for possession or distribution of cannabinoid medicine70     pursuant to an approved study.71          (1)  As used in this section:72          (a)  "Cannabinoid medicine" means a product intended for human ingestion that:73          (i)  contains an extract or concentrate that is obtained from cannabis;74          (ii)  is prepared in a medicinal dosage form; and75          (iii)  contains at least 10 units of cannabidiol for every one unit of tetrahydrocannabinol.76          (b)  "Cannabis" means any part of the plant cannabis sativa, whether growing or not.77          (c)  "Drug paraphernalia" means the same as that term is defined in Section 58-37a-3.78          (d)  "Expanded cannabinoid medicine" means a product intended for human ingestion79     that:80          (i)  contains an extract or concentrate that is obtained from cannabis;81          (ii)  is prepared in a medicinal dosage form; and82          (iii)  contains less than 10 units of cannabidiol for every one unit of83     tetrahydrocannabinol.84          (e)  "Medicinal dosage form" means:85          (i)  a tablet;86          (ii)  a capsule;87          (iii)  a concentrated oil;88          (iv)  a liquid suspension;89          (v)  a transdermal preparation; or90          (vi)  a sublingual preparation.91          (f)  "Tetrahydrocannabinol" means a substance derived from cannabis that meets the92     description in Subsection 58-37-4(2)(a)(iii)(AA).93          (2)  Notwithstanding any other provision of this chapter, an individual who possesses or94     distributes cannabinoid medicine or expanded cannabinoid medicine is not subject to the95     penalties described in this title for the possession or distribution of marijuana or96     tetrahydrocannabinol to the extent that the individual's possession or distribution of97     cannabinoid medicine or expanded cannabinoid medicine complies with Title 26, Chapter 59,98     Cannabinoid Medicine Research Act.99          Section 5.  Effective date.100          If approved by two-thirds of all the members elected to each house, this bill takes effect101     upon approval by the governor, or the day following the constitutional time limit of Utah102     Constitution, Article VII, Section 8, without the governor's signature, or in the case of a veto,103     the date of veto override.Legislative Review NoteOffice of Legislative Research and General Counsel

